Bay­er, Ori­on win speedy ap­proval for prostate can­cer drug daro­lu­tamide

Three months ahead of sched­ule, Bay­er and Finnish part­ner Ori­on’s prostate can­cer drug daro­lu­tamide has been cleared for use by the US reg­u­la­tor un­der pri­or­i­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER